Clinical Trial: Evaluation of Exhaled Breath Condensate in the Diagnosis of Invasive Pulmonary Aspergillosis

Study Status: Completed
Recruit Status: Completed
Study Type: Observational

Official Title:

Brief Summary: The purpose of this study is to evaluate the diagnostic potential of biomarkers for invasive pulmonary aspergillosis in exhaled breath condensate.

Detailed Summary: Invasive pulmonary aspergillosis (IPA) is a life-threatening infection in immunocompromised patients. The poor prognosis of the disease is partly attributed to difficulties encountered with the diagnosis of this infection. Invasive sampling procedures are often precluded in these patients. In addition, conventional diagnostic techniques lack sensitivity. Recently there has been increasing interest in the investigation of the lungs by noninvasive means including measurement of biomarkers in exhaled breath (e.g. NO) and those found in the cooled and condensed exhalate,termed EBC. It has been demonstrated that a measurable fraction of the EBC in healthy subjects is derived from aerosolized airway lining fluid. The presence of biomarkers for IPA will be investigated in EBC of patients with IPA, compared to controls.
Sponsor: Universitaire Ziekenhuizen Leuven

Current Primary Outcome: The identification of biomarkers for invasive pulmonary aspergillosis (IPA) in exhaled breath condensate (EBC) [ Time Frame: 15 months ]

Original Primary Outcome: The identification of biomarkers for IPA in EBC [ Time Frame: 15 months ]

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Universitaire Ziekenhuizen Leuven

Dates:
Date Received: November 23, 2010
Date Started: January 2011
Date Completion:
Last Updated: July 4, 2014
Last Verified: July 2014